The Myeloma Institute was the first to describe achievable cure.

total-treatmentThe Myeloma Institute was the first center to achieve curative outcomes through its novel Total Therapy treatment approach. Total Therapy incorporates proven agents up front for an “all-out attack” on myeloma in order to destroy the myeloma cells at the outset and not give them an opportunity to survive. Total Therapy has evolved to include variations that target specific molecular subtypes of myeloma.

Total Therapy has been the driving force behind our extensive translational research, incorporating a series of clinical trials that span more than two decades. We have observed enormous success with our Total Therapy Approach, as described in our numerous publications.

A New Total Approach

Using a full array of advanced diagnostics, including gene expression profiling, DNA and RNA sequencing and methylation analysis, we can identify the specifics of each patient’s disease at the molecular level.  This helps us predict how myeloma cells are likely to respond to different therapeutic agents and strategies.  These diagnostics allow us to develop precision medicine approaches based on incorporating targeted therapies that are individualized for each patient.  Through a targeted approach we can achieve deeper responses that will lead to cure for more patients.

With this advanced knowledge and new therapeutic agents, we are now taking Total Therapy to the next level and improving cure by developing the most effective, patient-specific regimen including:

  • Harnessing the immune system to overcome resistance to treatment
  • Targeting treatment to the molecular lesions that cause myeloma by altering signaling pathways that regulate the growth of cancer cells
  • Developing immunotherapy-based therapies to replace toxic chemotherapies
  • Personalizing treatment regimens for frailer patients who need a less strenuous approach
  • Using antibodies to identify markers of the best responders, which will help us target treatments to specific patient groups
  • Creating innovative studies for high-risk myeloma that will enable us to quickly assess how immunotherapy and targeted therapy impact responses so we can quickly integrate effective interventions into Total Therapy
  • Developing novel imaging studies that can provide information about response to treatment in a quick time frame so that treatment can be adjusted quickly